A Phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma

The current study was performed to assess whether sequential potentially noncross‐resistant chemotherapy prolongs disease‐free survival (DFS) and overall survival (OS) in patients with operable breast carcinoma.

[1]  B Fisher,et al.  Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. , 1997, Journal of the National Cancer Institute.

[2]  C. Osborne,et al.  Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Jones.  Adjuvant chemotherapy for breast cancer. , 1981, JAMA.

[4]  Terry L. Smith,et al.  Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  B Fisher,et al.  Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Sismondi,et al.  Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. , 1992, European journal of cancer.

[7]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[8]  G. Hortobagyi,et al.  Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. , 1979, JAMA.

[9]  R. Coombes,et al.  Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[11]  P. Carbone.  Adjuvant therapy of stage II breast cancer , 1990, Cancer.

[12]  Terry L. Smith,et al.  Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs , 1988, Cancer.

[13]  N. Boyd,et al.  Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Hortobagyi,et al.  Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Hortobagyi,et al.  Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer , 1983, Cancer.

[16]  R. Gelber,et al.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[18]  Terry L. Smith,et al.  Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette‐Guerin and with or without irradiation in operable breast cancer a prospective randomized trial , 1984, Cancer.

[19]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[20]  R. Pugh,et al.  Short‐term chemotherapy of poor‐prognosis metastatic breast cancer with three non‐cross resistant chemotherapy regimens. A southwest oncology group study , 1987, Cancer.

[21]  P. Sismondi,et al.  Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.